FDA approves Regeneron's gene therapy for inherited deafness
23/04/2026 17:42
April 23 (Reuters) - U.S. Food and Drug Administration has approved Regeneron's REGN.O gene therapy for a rare genetic form of deafness, the company said on Thursday. (Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)